Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001558370-23-004472
Filing Date
2023-03-23
Accepted
2023-03-23 17:00:25
Documents
5
Period of Report
2023-05-19

Document Format Files

Seq Description Document Type Size
1 PRE 14A tmb-20230519xpre14a.htm PRE 14A 689100
2 GRAPHIC tmb-20230519xpre14a001.jpg GRAPHIC 12602
3 GRAPHIC tmb-20230519xpre14a002.jpg GRAPHIC 203288
4 GRAPHIC tmb-20230519xpre14a003.jpg GRAPHIC 203434
5 GRAPHIC tmb-20230519xpre14a004.jpg GRAPHIC 188702
  Complete submission text file 0001558370-23-004472.txt   1527821
Mailing Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 617-336-7540
Sigilon Therapeutics, Inc. (Filer) CIK: 0001821323 (see all company filings)

EIN.: 474005543 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-39746 | Film No.: 23756943
SIC: 2834 Pharmaceutical Preparations